GAITHERSBURG, MD--(Marketwire - January 09, 2012) -
Noble Life Sciences, a provider of preclinical research services to the biotechnology and pharmaceutical industries, announced today the appointment of Mr. Alain Cappeluti, as the company's President. At the same time, the company announced the appointment of Dr. Kenneth Carter as the Chairman of the Board of Noble Life Sciences.
"I am delighted to lead Noble Life Sciences' experienced and talented team as we launch new services to expand our current offering," said Mr. Cappeluti. "A focus of our development efforts has been to establish a biomarker based platform that leverages validated cancer pathway biomarkers measured in cell lines and tumor tissues to predict and evaluate sensitivity to targeted therapeutics across cancer indications and molecular sub-types. This effort has been supported by a Translational Research Award we received in 2010 from The Department of Business and Economic Development, Maryland Biotechnology Center."
Mr. Cappeluti has more than 25 years of experience in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. Mr. Cappeluti was the second employee at HGS and was part of the team that spun out CoGenesys from HGS in 2006 until the company was sold to Teva Pharmaceuticals in 2008. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. He is also a co-founder and serves on the board of OTraces, Inc., an early stage cancer diagnostics company and is on the board of and serves as a consultant to other life science companies.
Dr. Carter remarked, "I am very pleased to assume the duties of Chairman of the Board of Noble Life Sciences as I move on to a new position as President and CEO of NexImmune. Mr. Cappeluti will take the lead at Noble Life Sciences during a very exciting time as the company expands its presence in the Maryland biotechnology market."
About Noble Life Sciences:
Noble Life Sciences provides in vitro and in vivo preclinical research services including experimental design and testing, disease models, selection and validation of biomarkers for personalized medicine, and vivarium services. With deep expertise in preclinical drug development, the company offers access to their top scientists who work collaboratively with researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions to expedite preclinical research and guide clinical development. For more information about Noble Life Sciences, visit www.noblelifesci.com.